To the Editor: We read with interest the paper by Hosonuma et al. "A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafi brate in patients with primary biliary cirrhosis and dyslipidemia" ( 1 ) on the combination therapy of bezafi brate (BF) and ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) and dyslipidemia, non-responder to the fi rst-line treatment with UDCA.
Th is represents an important issue because of the considerable number (up to 35% according to the last reports) of patients with refractory or with suboptimal biochemical response aft er the conventional therapy ( 2 ). Early biochemical response is well known to determine a signifi cant survival improvement in these patients, hence the fi ndings of the paper by Hosonuma et al. are certainly of interest to the hepatological community.
However, some safety concerns arise on the proposed combo therapy mainly owing to the increased risk of renal dysfunction, not completely reversible with its suspension. Furthermore, it should be noted that other therapeutic options are currently in use for non-responders to fi rst-line treatment.
In fact, in previous papers, the combination of UDCA and budesonide has been found to determine a signifi cant increase in biochemical response with respect to UDCA alone ( 3 ); hence, it would be interesting to Licinio et al. suggested the necessity of a randomized controlled trial (RCT) to compare the combination of bezafi brate (BF) and ursodeoxycholic acid (UDCA) with that of budesonide and UDCA as a second-line option for non-responders to a fi rst-line treatment with UDCA, with compare in a randomized-controlled trial (RCT) the regimen proposed by Hosonuma et al. with the current second-line option.
In our opinion, in attendance of a direct comparison between the two diff erent therapeutic regimens, the combination of UDCA and BF could be considered as second-line treatment in two particular subsets of patients, who are not optimal candidates to a budesonide-based therapy.
First: patients with dyslipidemia and at least one cardiologic risk factor. Usually, dyslipidemia alone does not lead to an increased risk of cardiovascular events in PBC patients, probably due to the circulation of an abnormal low-density lipoprotein (LDL), called LDL-X, able to preserve the endothelial integrity ( 4 ). However, as budesonide could impair the lipidic metabolism ( 5 ), a budesonide-free regimen could result safer and equally eff ective in dyslipidemic patients with other cardiovascular risk factors. Th e second subset of potential candidates to UDCA-BF combo treatment includes those with a pathologic bone mineral density, where budesonide could be detrimental for the bone metabolism ( 6 ).
In conclusion, the paper by Hosonuma et al. paves the way to a new therapeutic option in non-responders to fi rst-line treatment, but broad RCTs are warranted in order to correctly defi ne the therapeutic algorithm of PBC patients.
